VIA
NRIX icon

Virtus Investment Advisers’s Nurix Therapeutics NRIX Stock Holding History

Virtus Investment Advisers’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$222K Buy
14,299
+350
+3% +$5.8K 0.06% 328
2025
Q4 		$265K Buy
13,949
+4,435
+47% +$63.7K 0.07% 304
2025
Q3 		$87.9K Buy
9,514
+1,652
+21% +$17.2K 0.03% 430
2025
Q2 		$89.5K Sell
7,862
-124
-2% -$1.34K 0.03% 380
2025
Q1 		$94.9K Buy
+7,986
New +$134K 0.03% 429

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Virtus Investment Advisers's NRIX Position: Q1 2026 in Review

Virtus Investment Advisers increased its Nurix Therapeutics (NRIX) stake by 2.5% in Q1 2026, buying an estimated $5.8K and bringing the position to 14,299 shares worth $222K. The position accounts for 0.06% of the portfolio, ranked #328.

Virtus Investment Advisers first reported a position in NRIX in Q1 2025 and has held it in 5 quarters since. The position peaked at $265K in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Virtus Investment Advisers held 14,299 shares of Nurix Therapeutics worth $222K as of Q1 2026.
  • Virtus Investment Advisers bought 350 Nurix Therapeutics shares in Q1 2026, an estimated $5.8K.
  • Nurix Therapeutics made up 0.06% of Virtus Investment Advisers's portfolio in Q1 2026, its #328 holding.
  • Virtus Investment Advisers first reported a position in Nurix Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Virtus Investment Advisers's Nurix Therapeutics position peaked at $265K in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.